(NASDAQ: VERU) Is Our Top Watch Today. Here's Why:

Veru is moving toward a potentially important 2027 catalyst in the booming obesity-drug market. Its Phase 2b PLATEAU trial is now fully enrolled with 239 patients, exceeding its original 200-patient target, and an interim analysis of lean body mass and fat mass is expected in Q1 2027. The trial is testing oral enobosarm alongside semaglutide in older adults with obesity, with the goal of preserving muscle and physical function while potentially generating greater fat and overall weight loss. Veru also recently strengthened the program with a Novo Nordisk clinical-supply agreement and a favorable USPTO patent decision covering enobosarm/semaglutide treatment methods.

GLP-1 drugs have transformed obesity treatment, but the quality of that weight loss is becoming an increasingly important issue. Research reviews published in 2025 and 2026 have highlighted that skeletal or lean-mass loss can accompany GLP-1-driven weight reduction, with particular concern for older or frail patients who already face sarcopenia risk. Veru is trying to address that bottleneck rather than compete directly with GLP-1s: enobosarm is designed as an adjunct to drugs such as semaglutide, aiming to shift more of the weight loss toward fat while preserving lean mass, physical function and potentially bone. If that concept holds up in larger trials, it could address an important unmet need created by the enormous adoption of incretin-based obesity therapies.

Veru is a late-clinical-stage biopharmaceutical company developing medicines for cardiometabolic and inflammatory diseases. Its pipeline centers on two late-stage small molecules: enobosarm, an oral selective androgen receptor modulator being developed alongside GLP-1 therapies for higher-quality weight reduction, and sabizabulin, an oral microtubule disruptor being investigated as an anti-inflammatory therapy for atherosclerotic cardiovascular disease.

Veru's differentiation is that it isn't trying to build another GLP-1 competitor. Instead, it's attempting to become the muscle-preserving companion therapy to the existing GLP-1 class. Its studies look beyond the number on the scale by measuring fat mass, lean mass, physical function, mobility and bone mineral density. The company has already reported positive results from its earlier Phase 2b QUALITY study, while PLATEAU is designed to determine whether those body-composition benefits translate into clinically meaningful incremental weight loss over semaglutide alone. That is a potentially differentiated position, although superiority to competing obesity strategies has not yet been established, and the upcoming clinical data remain the key test.

Disclaimer: Sponsored Content

Trader's Incentive is a subsidiary of Parabolic Equities LLC (the “Publisher”). The Publisher received Six Thousand USD in cash via wire transfer from Bullish Media LLC ("Bullish Media") for a one day campaign beginning and ending on September Eighth Twenty Twenty Six, before the deduction of any applicable bank wire, PayPal, Wise, or electronic payment processing fees, in exchange for the publication and dissemination of the Information (as defined in the full disclaimer linked below). Bullish Media LLC, in turn, received funding acting on behalf of and with funding provided by the Issuer. All compensation received is strictly cash. Neither the Publisher nor Bullish Media LLC received any equity compensation, stock options, warrants, or securities-based consideration of any kind from the Issuer or any intermediary. Read the full disclaimer here: